IGF2 is an actionable target that identifies a distinct subpopulation of colorectal cancer patients with marginal response to anti-EGFR therapies
出版年份 2015 全文链接
标题
IGF2 is an actionable target that identifies a distinct subpopulation of colorectal cancer patients with marginal response to anti-EGFR therapies
作者
关键词
-
出版物
Science Translational Medicine
Volume 7, Issue 272, Pages 272ra12-272ra12
出版商
American Association for the Advancement of Science (AAAS)
发表日期
2015-01-29
DOI
10.1126/scitranslmed.3010445
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Randomized Phase Ib/II Trial of Rilotumumab or Ganitumab with Panitumumab versus Panitumumab Alone in Patients with Wild-type KRAS Metastatic Colorectal Cancer
- (2014) E. Van Cutsem et al. CLINICAL CANCER RESEARCH
- Blockade of EGFR and MEK Intercepts Heterogeneous Mechanisms of Acquired Resistance to Anti-EGFR Therapies in Colorectal Cancer
- (2014) S. Misale et al. Science Translational Medicine
- HER2 gene copy number status may influence clinical efficacy to anti-EGFR monoclonal antibodies in metastatic colorectal cancer patients
- (2013) V Martin et al. BRITISH JOURNAL OF CANCER
- KRAS gene amplification in colorectal cancer and impact on response to EGFR-targeted therapy
- (2013) Emanuele Valtorta et al. INTERNATIONAL JOURNAL OF CANCER
- Use of Early Tumor Shrinkage to Predict Long-Term Outcome in Metastatic Colorectal Cancer Treated With Cetuximab
- (2013) Hubert Piessevaux et al. JOURNAL OF CLINICAL ONCOLOGY
- Which drug, and when, for patients with BRAF-mutant melanoma?
- (2013) Sekwon Jang et al. LANCET ONCOLOGY
- Anticancer IGF1R classes take more knocks
- (2013) Malini Guha NATURE REVIEWS DRUG DISCOVERY
- Panitumumab–FOLFOX4 Treatment and RAS Mutations in Colorectal Cancer
- (2013) Jean-Yves Douillard et al. NEW ENGLAND JOURNAL OF MEDICINE
- Amplification of the MET Receptor Drives Resistance to Anti-EGFR Therapies in Colorectal Cancer
- (2013) Alberto Bardelli et al. Cancer Discovery
- Inhibition of MEK and PI3K/mTOR Suppresses Tumor Growth but Does Not Cause Tumor Regression in Patient-Derived Xenografts of RAS-Mutant Colorectal Carcinomas
- (2012) G. Migliardi et al. CLINICAL CANCER RESEARCH
- Small-molecule ATP-competitive dual IGF-1R and insulin receptor inhibitors: structural insights, chemical diversity and molecular evolution
- (2012) Meizhong Jin et al. Future Medicinal Chemistry
- Dual Targeting of the Epidermal Growth Factor Receptor Using the Combination of Cetuximab and Erlotinib: Preclinical Evaluation and Results of the Phase II DUX Study in Chemotherapy-Refractory, Advanced Colorectal Cancer
- (2012) Andrew J. Weickhardt et al. JOURNAL OF CLINICAL ONCOLOGY
- Overall Survival Benefit With Lapatinib in Combination With Trastuzumab for Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer: Final Results From the EGF104900 Study
- (2012) Kimberly L. Blackwell et al. JOURNAL OF CLINICAL ONCOLOGY
- LAS: A Software Platform to Support Oncological Data Management
- (2012) Elena Baralis et al. JOURNAL OF MEDICAL SYSTEMS
- Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial
- (2012) José Baselga et al. LANCET
- Direct and immune mediated antibody targeting of ERBB receptors in a colorectal cancer cell-line panel
- (2012) S. Q. Ashraf et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Compensatory Pathways in Oncogenic Kinase Signaling and Resistance to Targeted Therapies: Six Degrees of Separation: Figure 1.
- (2012) Livio Trusolino et al. Cancer Discovery
- Genetic and Expression Analysis of MET, MACC1, and HGF in Metastatic Colorectal Cancer: Response to Met Inhibition in Patient Xenografts and Pathologic Correlations
- (2011) F. Galimi et al. CLINICAL CANCER RESEARCH
- Activation of ERBB2 Signaling Causes Resistance to the EGFR-Directed Therapeutic Antibody Cetuximab
- (2011) K. Yonesaka et al. Science Translational Medicine
- A Molecularly Annotated Platform of Patient-Derived Xenografts ("Xenopatients") Identifies HER2 as an Effective Therapeutic Target in Cetuximab-Resistant Colorectal Cancer
- (2011) A. Bertotti et al. Cancer Discovery
- A Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell Subpopulations
- (2010) Sreenath V. Sharma et al. CELL
- Association of KRAS p.G13D Mutation With Outcome in Patients With Chemotherapy-Refractory Metastatic Colorectal Cancer Treated With Cetuximab
- (2010) Wendy De Roock et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Randomized, Phase II Study of the Insulin-Like Growth Factor-1 Receptor Inhibitor IMC-A12, With or Without Cetuximab, in Patients With Cetuximab- or Panitumumab-Refractory Metastatic Colorectal Cancer
- (2010) Diane Lauren Reidy et al. JOURNAL OF CLINICAL ONCOLOGY
- Pharmacogenomic and Pharmacoproteomic Studies of Cetuximab in Metastatic Colorectal Cancer: Biomarker Analysis of a Phase I Dose-Escalation Study
- (2010) Josep Tabernero et al. JOURNAL OF CLINICAL ONCOLOGY
- Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis
- (2010) Wendy De Roock et al. LANCET ONCOLOGY
- KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer
- (2010) Wendy De Roock et al. LANCET ONCOLOGY
- Radiological tumor size decrease at week 6 is a potent predictor of outcome in chemorefractory metastatic colorectal cancer treated with cetuximab (BOND trial)
- (2009) H. Piessevaux et al. ANNALS OF ONCOLOGY
- Epidermal Growth Factor Receptor (EGFR) gene copy number (GCN) correlates with clinical activity of irinotecan-cetuximab in K-RAS wild-type colorectal cancer: a fluorescence in situ (FISH) and chromogenic in situ hybridization (CISH) analysis
- (2009) Mario Scartozzi et al. BMC CANCER
- Analysis of PTEN, BRAF, and EGFR Status in Determining Benefit From Cetuximab Therapy in Wild-Type KRAS Metastatic Colon Cancer
- (2009) Pierre Laurent-Puig et al. JOURNAL OF CLINICAL ONCOLOGY
- Amphiregulin and Epiregulin mRNA Expression in Primary Tumors Predicts Outcome in Metastatic Colorectal Cancer Treated With Cetuximab
- (2009) Bart Jacobs et al. JOURNAL OF CLINICAL ONCOLOGY
- BMS-754807, a small molecule inhibitor of insulin-like growth factor-1R/IR
- (2009) J. M. Carboni et al. MOLECULAR CANCER THERAPEUTICS
- Only a Subset of Met-Activated Pathways Are Required to Sustain Oncogene Addiction
- (2009) A. Bertotti et al. Science Signaling
- Wild-TypeBRAFIs Required for Response to Panitumumab or Cetuximab in Metastatic Colorectal Cancer
- (2008) Federica Di Nicolantonio et al. JOURNAL OF CLINICAL ONCOLOGY
- Wild-TypeKRASIs Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer
- (2008) Rafael G. Amado et al. JOURNAL OF CLINICAL ONCOLOGY
- K-rasMutations and Benefit from Cetuximab in Advanced Colorectal Cancer
- (2008) Christos S. Karapetis et al. NEW ENGLAND JOURNAL OF MEDICINE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search